Replies to post #186067 on Biotech Values

[masterlongevity]

Im aggressively investing in many names this year. probably a little late in the cycle, but im going for it.

[DewDiligence]

In due course, the NASH market will almost certainly have multiple approved products.

p.s. ENTA just announced a preclinical FXR compound that's similar to ICPT's OCA.